1 / 7

CAR T Cell Therapy Market

CAR-T cell therapy involves genetically modifying a patient's own T-cells to express a chimeric antigen receptor (CAR) on their surface. This CAR enables T-cells to recognize and bind to specific cancer cell antigens, leading to their destruction. The modified CAR-T cells are then infused back into the patient's body, where they multiply and initiate a potent immune response against cancer cells.

Sumedha4
Download Presentation

CAR T Cell Therapy Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GLOBAL CAR T CELL THERAPY MARKET Market Size (2017E) US$ 0.07 BN CAGR (2019–2028) 46.1% Market Size (2028F) US$ 8.5 BN

  2. Segmentation (Scope) Therapeutic Application Targeted Antigen • Acute Lymphocytic Leukemia • CD 19 • Chronic Lymphocytic Leukemia • CD 20 • Non Hodgkin Leukemia • GD2 • Multiple Myeloma • CD 22 • Pancreatic Cancer • CD 30 • Neuroblasta • CD 33 • Breast Cancer • HER 1 • Acute Myeloid Leukemia • HER 2 • Hepatocellular Carcinoma • Meso • Colorectal Cancer • EGFRvIII • Others • Others © Coherent Market Insights. All Rights Reserved

  3. Key Facts • Adult population account for over 40% cases of all • Each year, over 171,000 people are diagnosed with blood cancer in the U.S. • Kite Pharma established 43,500 square foot plant in the U.S.- expected to produce up to 5000 patient therapy products in 2018 • FDA approval of products being developed by Kite Pharma and Novartis for CD30 and CD22 expected by 2025 © Coherent Market Insights. All Rights Reserved

  4. Market Purview • As of 2016, just over 40 companies are engaged in research in the CAR T cell therapy market • Expected to act as a lifesaving drug for over 30 million patients’ suffering from lymphoma • First product launch expected in 2017 © Coherent Market Insights. All Rights Reserved

  5. Few Leading Companies Novartis international AG Kite Pharma Inc. Juno Therapeutics Cellectis © Coherent Market Insights. All Rights Reserved

  6. Global Car T Cell Therapy Market Share (%), By Type, 2021 32.5% ? ? ? ? Abecma Kymriah Yescarta Breyanzi Tecartus © Coherent Market Insights. All Rights Reserved

More Related